

Chromogranin A (ZM12) Mouse Monoclonal Antibody
For *In Vitro* Diagnostic Use (IVD)

Product Identification

| | |
|---------|----------------------|
| Z2347ML | 1.0 ml (Concentrate) |
| Z2347MS | 0.5 ml (Concentrate) |
| Z2347MT | 0.1 ml (Concentrate) |
| Z2347MP | 7 mL (pre-dilute) |

Intended Use

This antibody is intended for *in vitro* diagnostic (IVD) use. Chromogranin A (ZM12) Mouse Monoclonal Primary Antibody is intended for professional laboratory use in the detection of the Chromogranin A protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing.

This antibody is intended to be used after the primary diagnosis of the tumor has been made by conventional histopathology using non-immunological histochemical stains. A qualified pathologist must interpret the results using this product to aid diagnosis in conjunction with the patient's relevant clinical history, other diagnostic tests, and proper controls.

Summary and Explanation

Chromogranin A is present in neuroendocrine cells throughout the body, including the neuroendocrine cells of the large and small intestine, adrenal medulla and pancreatic islets. It is an excellent marker for carcinoid tumors, pheochromocytomas, paragangliomas, and other neuroendocrine tumors. Co-expression of chromogranin A and neuron specific enolase (NSE) is common in neuroendocrine neoplasms. Reportedly, co-expression of certain keratins and chromogranin indicates neuroendocrine lineage. The presence of strong anti-chromogranin staining, and absence of anti-keratin staining should raise the possibility of paraganglioma. The co-expression of chromogranin and NSE is typical of neuroendocrine neoplasms. Most pituitary adenomas and prolactinomas readily express chromogranin.

Principle of Method

Chromogranin A (ZM12) Mouse Monoclonal Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow visualization of antigens by sequentially applying a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex, and a chromogenic substrate, with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes,

which may or may not be associated with a particular antigen.

Materials Provided

Chromogranin A (ZM12) Mouse Monoclonal Antibody in concentrated form or prediluted

Antibody Specifications:

Antibody as Purified antibody diluted in Tris-HCl buffer containing stabilizing protein and <0.1% ProClin.

Host: Mouse

Isotype: IgG2b / κ

Immunogen: Recombinant human Chromogranin A protein

Cellular Localization: Cytoplasmic

Concentrate Dilution Range: 1:100-200

Positive control: Pancreas or neuroendocrine tumor

Storage and Handling

Upon receiving, store the vial at 2–8°C. When stored at 2–8°C, this antibody is stable for 24 months.

Additional studies on heat and freeze/thaw cycles support that the products are stable through a range of temperature exposures of 45 °C to -40 °C. Contact Zeta Corporation for more information if necessary.

To ensure proper reagent stability and functionality, immediately after use, the cap must be replaced and the bottle placed in a refrigerator in an upright position. Please do not use it after the expiration date is stamped on the vial. If reagents are stored under conditions other than those specified in the package insert, the user must validate them. Repeated freeze-thaw cycles may decrease antibody activity and should be avoided.

If packaging or contents appear broken or damaged, do not use them and contact Zeta Corporation. Contact information is on the last page of this document.

Reconstitution

Predilute Antibodies: Ready to use; no reconstitution necessary.

Concentrate Antibodies: Refer to the established dilution range 1:100-200 and use an appropriate lab-standardized diluent and container. Refer to the label for any specific instructions. Stability after dilution: 7 days at 24°C, three months at 2–8°C, and six months at -20°C as demonstrated by stability studies performed at Zeta Corporation when using polypropylene containers.

Materials Required but not Provided

1. Positive Tissue Control: Routinely processed, neutral-buffered formalin-fixed, paraffin-embedded Pancreas or neuroendocrine tumor
2. Negative tissue control (internal or external)
3. Microscope slides and coverslips
4. Staining jars or baths

5. Timer
6. Xylene or xylene substitute
7. Ethanol or reagent alcohol
8. Deionized or distilled water
9. Heating equipment or enzyme for the tissue pretreatment step
10. Detection system
11. Chromogen
12. Wash Buffer
13. Hematoxylin
14. Antibody diluents
15. Peroxide Block
16. Light Microscope
17. Mounting medium
18. Avidin-Biotin Blocking Reagents for use with streptavidin-biotin detection

Specimen Preparation for Analysis

Routinely processed, neutral-buffered formalin-fixed, and paraffin-embedded tissue sections are used with this primary antibody. Approximately 4 μm tissue sections are preferred and should be placed on positively charged slides. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval is recommended. Results may vary due to prolonged fixation, unexpected foreign materials, or interfering substances. Decalcification may also affect the staining results.

Tissues from persons infected with the hepatitis B virus containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.

Immunohistochemistry protocol

1. Deparaffinization
2. Rehydration
3. Peroxide block: Block for 5 minutes at ambient temperature
4. Wash with Zeta Tris Buffered Saline plus Tween 20 pH 7.4 (ZD5).
5. Epitope Retrieval Technique: Zeta Tris-EDTA HIER Solution pH 9.0 (ZD6) at 100°C for 40 minutes using a pressure cooker. Refer to the commercially available device data sheet for specific instructions.
6. Rinse with deionized water. Wash with Zeta Tris Buffered Saline plus Tween 20 pH 7.4 (ZD5).
7. Primary antibody: Incubate for 30 minutes at ambient temperature.
8. Wash with Zeta Tris Buffered Saline plus Tween 20 pH 7.4 (ZD5).
9. Zeta Universal HRP Polymer Detection Kit with DAB (ZD11): Incubate for 30 minutes at ambient temperature.
10. Wash with Zeta Tris Buffered Saline plus Tween 20 pH 7.4 (ZD5). Rinse with deionized water
11. Chromogen: Incubate for 5 minutes at ambient temperature
12. Rinse with deionized water

13. Counterstain with hematoxylin. Rinse with deionized water

Warnings and Precautions

1. Take reasonable precautions when handling reagents. Use disposable gloves and lab coats when handling suspected carcinogens or toxic materials (for example: xylene).
2. Avoid contact with reagents with the eyes and mucous membranes. If reagents contact sensitive areas, wash with copious amounts of water.
3. Patient specimens and all materials contacting them should be handled as biohazardous materials and disposed of with proper precautions. Never pipette by mouth.
4. The user must validate incubation times and temperatures.
5. The prediluted, ready-to-use reagents are optimally diluted, and further dilution may result in loss of antigen staining.
6. The concentrated reagents may be diluted optimally based on validation by the user. Any diluent used that is not explicitly recommended herein must likewise be validated by the user for compatibility and effect on stability.
7. This product is not classified as hazardous when used according to instructions. The preservative in the reagent is less than 0.05% ProClin and does not meet the OSHA (USA) criteria for the hazardous substance at the stated concentration. However, the presence of the Proclin may cause an allergic skin reaction. Refer to Zeta Corporation's website's Safety Data Sheet (SDS).
8. The user must validate storage conditions other than those specified in the package insert.
9. Diluent and product may contain bovine serum albumin (BSA). The BSA used to manufacture the diluent and product is purchased from commercial suppliers that source the BSA from countries where TSE is not endemic. The BSA states that the bovine sources are from countries with negligible BSE risk, and state bovine sources from the USA and Canada. Zeta uses recombinant production for its antibodies in characterized non-human cell lines, and no animal products other than BSA in the diluent are used in its manufacturing processes.
10. As with any product derived from biological sources, proper handling procedures should be used.
11. Product disposal should be in accordance with applicable national, state, and local laws and regulations. Local regulations may be more stringent than national or state requirements. Verify local and state regulations before discharging into public sewers or landfills. Do not dump into any body of water. Contact a licensed professional waste disposal service for appropriate methods of disposal.

Quality Control Procedures

Positive Tissue Control

A positive tissue control must be run with every staining procedure performed. This tissue may contain positive- and negative-staining cells or components and serve as positive- and negative-control tissue. External Positive control materials should be fresh autopsy/ biopsy/ surgical specimens fixed, processed, and embedded as soon as possible in the same manner as the patient sample(s). Positive tissue controls indicate correctly prepared tissues and

proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to detect subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and detecting minor reagent degradation levels.

Negative Tissue Control

Internal or external negative tissue control may be used depending on the organization's guidelines and policies to which the end-user belongs. The variety of cell types in many tissue sections offers internal negative control sites, but the user should verify this. The components that do not stain should demonstrate the absence of specific staining and indicate non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Patient Tissue

Patient specimens should be examined last. Positive staining intensity should be assessed within the context of any nonspecific background staining of the negative reagent control. As with any immunohistochemical test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells/tissue assayed. If necessary, use a panel of antibodies to identify false-negative reactions.

Interpretation of Results

The immunostaining procedure causes a colored reaction product to precipitate at the antigen sites localized by the primary antibody. Refer to the appropriate detection system package insert for expected color reactions. A licensed pathologist experienced in immunohistochemistry procedures must evaluate the control tissues before interpreting results.

Positive Tissue Control

The stained positive control should be examined first to ensure all reagents function properly. The presence of an appropriately colored reaction product within the target cells or markers indicates positive reactivity. Refer to the package insert of the detection system used for color reactions.

Excessive or incomplete staining may compromise the proper interpretation of results. If positive tissue control fails to demonstrate appropriate positive staining, any results with the specimens are considered invalid.

Negative Tissue Control

The negative tissue control (internal or external) should be examined to verify the primary antibody's specific labeling of the target antigen after the positive tissue control. The absence of specific staining in the negative tissue control confirms that the antibody does not cross-react with cells or cellular components. If specific staining occurs in the negative tissue control, results with the patient specimen are considered invalid.

Patient Tissue

Patient tissues should be examined next. Positive staining should be assessed within the context of any background staining of the (internal) negative control. As with any immunohistochemical test, a negative result means that the antigen in question was not detected, not that the antigen is absent in the cells or tissue

assayed. A panel of antibodies may aid in identifying false-negative reactions. A qualified pathologist must interpret the patient's results based on morphologic findings and relevant clinical data.

Limitations

1. This reagent is for professional laboratory use only, as immunohistochemistry is a multiple-step process that requires specialized training in selecting the appropriate reagents, tissues, fixation, processing, preparation of the immunohistochemistry slide, and interpretation of the staining results.
2. For *in vitro* diagnostic use.
3. Tissue staining is dependent on the handling and processing of the tissue before staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning, or contamination with other tissues or fluids may produce artifacts, antibody trapping, or false-negative results. Inconsistent results may result from variations in fixation and embedding methods and inherent irregularities within the tissue.
4. Excessive or incomplete counterstaining may compromise the proper interpretation of results.
5. The clinical interpretation of any positive staining, or its absence, must be evaluated within the context of clinical history, morphology, other histopathological criteria, and other diagnostic tests. This antibody is intended to be used in a panel of antibodies if applicable. A qualified pathologist must be familiar with the antibodies, reagents, diagnostic panels, and methods used to produce the stained preparation. Staining must be performed in a certified, licensed laboratory under the supervision of a pathologist who is responsible for reviewing the stained slides and assuring the adequacy of positive and negative controls.
6. Zeta provides antibodies in concentrated and prediluted formats at optimal dilution. Please refer to Dilution Range and Reconstitution on pages 1 and 2. Any deviation from recommended test procedures may invalidate expected results. Appropriate controls must be employed and documented. Users, in any circumstance, must accept responsibility for interpreting patient results.
7. Zeta provides some antibodies in a concentrated format so that the user may subsequently optimally dilute them for use, subject to the user's determination and adherence to suitable validation techniques. Users must validate the use of diluents other than those recommended herein (see Dilution Range). Users must, in any circumstance, accept responsibility for interpreting patient results.
8. Reagents may demonstrate unexpected reactions in previously untested tissues. The possibility of unforeseen reactions, even in tested tissue groups, cannot be eliminated because of the biological variability of antigen expression in neoplasms or other pathological tissues.
9. Tissues from persons infected with the hepatitis B virus containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.
10. When used in blocking steps, normal sera from the same animal source as the secondary antisera may cause false negative or false positive results because of autoantibodies or natural antibodies.
11. False-positive results may be seen because of the non-immunological binding of proteins or substrate reaction products. They may also be caused by pseudoperoxidase activity

(erythrocytes), endogenous peroxidase activity (cytochrome C), or endogenous biotin (for example, liver, brain, breast, or kidney), subject to the type of immunostaining technique used.

12. As with any immunohistochemistry test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells or tissue assayed.
13. The prediluted antibody products are optimized as ready-to-use products. Because of variation in tissue fixation and processing, it may be necessary to increase or decrease the primary antibody incubation time for individual specimens.
14. Combined with detection systems and accessories, this antibody detects antigen(s) that survive routine formalin fixation, tissue processing, and sectioning. Users who deviate from recommended test procedures *remain, as they would in any circumstance, responsible for interpreting and validating patient results.*
15. For laboratory use only.

Performance Characteristics

Neuroendocrine cells, neuroendocrine tumors

| Tissue Types | Chromogranin A Positive (%) |
|--------------------------------|-----------------------------|
| Solid pseudopapillary neoplasm | 0/102 (0) |
| Serous cystic neoplasm | 0/60 (0) |
| Pancreatoblastoma | 7/13 (54) |
| Acinar cell carcinoma | 19/111 (17) |

Excerpt: Chu, Peiguo, and Lawrence M Weiss. Modern Immunohistochemistry. 2nd ed., Cambridge, Cambridge University Press, 2014, pp.1-479.

The intended purpose, characteristics, and outcome of each

antibody are unique, and therefore, the results of staining should be assessed and interpreted appropriately by a licensed pathologist.

References

1. Fischer-Colbrie R, et al. Neuroscience. 1985; 16:547-55.
2. Hearn SA. J Histochem Cytochem. 1987; 35:795-801.
3. Wilson BS, et al. Am J Pathol. 1984; 115:458-68.







Please consult the manufacturer or competent authority if the user experiences technical or performance-related issues. Any severe incident about the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Document #: IFU-IVDL-Z2347

Version: Rev05

Date of issue: 18-Dec-2025

Symbol Glossary

| Symbol | Definition |
|---|------------------------------|
|  | Expiration Date |
|  | Lot Number |
|  | Catalog Number |
|  | Consult Instructions for Use |
|  | Temperature Limit |
|  | Caution: Skin Sens. 1 (H317) |



Zeta Corporation
605 E Huntington Dr. STE# 204
Monrovia, CA 91016, USA
Tel: (626) 355-2053
<http://www.zeta-corp.com>



UKRP

Emergo (UK) Consulting Limited
Cr360 – UL International
Compass House, Vision Park Histon
Cambridge, CB24 9BZ
United Kingdom



Emergo by B.V.
Westervoortsedijk
60 6827 AT,
Arnhem
The Netherlands



MedEnvoy Global BV
Prinses Margrietplantsoen
33 Suite 123
2295 AM, The Hague
The Netherlands